DraftBlue Cross Blue Shield - Rhode IslandPolicy N/A

Intracoronary Drug Delivery Balloon Procedures (Drug-Coated Balloons)

This policy governs coverage determinations for intracoronary drug delivery balloon procedures (eg, drug-coated or drug-eluting balloons) for coronary indications and applies to Medicare Advantage and commercial members of Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyIntracoronary Drug Delivery Balloon Procedures (Drug-Coated Balloons)

Policy CodePolicy N/A

Change TypeRoutine review — no material changes

Effective DateSep 1, 2026

Next Review DateJun 5, 2026

Key ActionVerify member benefits and eligibility per the evidence of coverage or subscriber agreement before scheduling or billing for intracoronary drug-delivery balloon procedures.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Not coveredMedicare Advantage coverage stance

Not medically necessaryCommercial coverage stance

2 codesProcedure codes listed

InsufficientEvidence conclusion

Coverage Determinations

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medicare Advantage coverage determination

Coverage stance for Medicare Advantage plans

Medicare Advantage: Intracoronary Drug Delivery Balloon Procedures are not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial product coverage determination

Coverage stance for commercial products

Commercial: Intracoronary Drug Delivery Balloon Procedures are considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

Intracoronary drug delivery balloon procedures (eg, drug-coated or drug‑eluting balloons) are not covered or not medically necessary under this policy because the available evidence is insufficient to determine their effects on health outcomes.

For commercial members, intracoronary drug‑delivery balloon procedures are considered not medically necessary. This determination is based on an overall conclusion that the evidence is insufficient to demonstrate improved clinical outcomes compared with alternative therapies, and therefore these procedures do not meet coverage criteria for commercial products.

Procedure and Billing Codes

Intracoronary drug-delivery balloon procedure codesHCPCS

0913T

Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (eg, drug-coated, drug-eluting), including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch

0914T

Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (eg, drug-coated, drug-eluting) performed on a separate target lesion from the target lesion treated with balloon angioplasty, coronary stent placement or coronary atherectomy, including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch (List separately in addition to code for percutaneous coronary stent or atherectomy intervention)

Provider Actions and Billing Guidance

Prior Authorization

Prior authorization

Not applicable — no prior authorization is required under this policy. Verify member-specific requirements as benefits may vary by contract.

Denial Risk

Coverage denials possible

Intracoronary Drug Delivery Balloon Procedures are not covered for Medicare Advantage members and are considered not medically necessary for Commercial members. There is a risk of coverage denial when submitting claims for these procedures; confirm member plan coverage before scheduling.

Medicare Advantage: Intracoronary Drug Delivery Balloon Procedures — not covered
Commercial: Intracoronary Drug Delivery Balloon Procedures — not medically necessary

Step Therapy

Step therapy

No step therapy requirements are specified in this policy.

Documentation Required

Benefits verification

Verify member benefits and eligibility before providing services. Consult the provider call center for member-specific coverage and to confirm whether services are a covered benefit under the member's Evidence of Coverage or Subscriber Agreement.

Check Evidence of Coverage / Subscriber Agreement for applicable coverage
Contact provider call center for member-specific determinations

Background and Clinical Context

Drug‑coated balloons (DCBs) are semicompliant angioplasty balloons coated with antiproliferative agents (for example, paclitaxel, sirolimus, or everolimus) embedded in a carrier matrix that transfers drug to the coronary vessel wall during balloon inflation. DCBs are designed to inhibit neointimal hyperplasia without leaving a permanent stent and have been evaluated particularly for treatment of in‑stent restenosis (ISR) and other coronary indications.

Definitions

Drug-coated balloon (DCB) — definition and key features

DefinitionA semicompliant balloon coated with antiproliferative agents (eg, paclitaxel, sirolimus, everolimus) embedded in a carrier matrix that transfers drug to the coronary vessel wall during inflation without leaving a permanent implant.

Primary purposeDeliver localized antiproliferative drug to inhibit neointimal hyperplasia while avoiding additional metallic stent layers.

Typical drugsPaclitaxel, sirolimus, or everolimus.

Mechanism of actionDrug rapidly diffuses from the balloon surface into the vessel wall during inflation to inhibit smooth muscle proliferation.

Clinical advantageProvides local drug delivery without permanent stent implantation, potentially preserving vessel architecture and future treatment options.

In-stent restenosis (ISR) — definition and clinical description

DefinitionRecurrent narrowing within a previously implanted coronary stent due to neointimal hyperplasia, neoatherosclerosis, and vessel remodeling.

PathophysiologyCombination of smooth muscle cell proliferation, inflammatory response to stent-related vessel injury, neoatherosclerosis, and remodeling.

Clinical consequencesMay cause recurrent angina and ischemia and often requires repeat revascularization.

Risk factorsLong stents, diabetes, and complex lesion anatomy increase ISR risk.

Management challengeMultilayer or small-vessel ISR is difficult to treat because additional stent layers can compromise lumen diameter and future options.